NASDAQ · RNAZ
TransCode Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for RNAZ: Nov 13, 2026
TransCode Therapeutics, Inc. Common Stock is estimated to report earnings on 11/13/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. The reported EPS for the same quarter last year was $-5.49.
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · RTTNews · Zacks- Fintel · Oct 29, 4:38 AM EDTTransCode Therapeutics, Inc. Initiates Strategic Process to Maximize Value of TTX-MC138 and Oncology PortfolioTransCode Therapeutics, Inc. announced that its Board of Directors has initiated a formal strategic process to evaluate opportunities designed to maximize the value of the Company and its oncology portfolio, including its lead product candidate, TTX-MC138. The process will evalua
- RTTNews · Oct 26, 11:18 AM EDTTransCode Reports Phase 1a Data For TTX-MC138 In Advanced Solid Tumors(RTTNews) – TransCode Therapeutics, Inc. (RNAZ) presented Phase 1a clinical data for TTX-MC138, an investigational RNA-based therapy targeting metastatic cancers, at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain.
- RTTNews · Oct 13, 9:15 AM EDTNatera, TransCode Target Residual Colorectal Cancer With Trial Collaboration(RTTNews) – Natera, Inc. (NTRA) and TransCode Therapeutics, Inc. (RNAZ) have entered into a strategic collaboration to support patient enrollment in TransCode's Phase 2a trial evaluating TTX-MC138 in colorectal cancer (CRC).
- RTTNews · Aug 18, 9:59 PM EDTAfter-Hours Biotech Gainers: TNON, BIVI, EDSA, RNAZ, HCWB(RTTNews) – Today's after-hours gainers include Tenon Medical, which recently reported its second-quarter results and implemented a reverse stock split; BioVie, which is developing a drug for early-stage Parkinson's disease; and Edesa Biotech, which is advancing EB06, a potential
- RTTNews · Jul 9, 10:50 PM EDTTop Biotech Gainers: VRAX Jumps 100% After Fosun Deal, FBRX Soars On Vitiligo Data, TRAX On Watch(RTTNews) – Today's top biotech gainers include Virax Biolabs, following its agreement with Fosun Diagnostics; Forte Biosciences, after reporting positive vitiligo data; Connect Biopharma, with a key near-term catalyst ahead; and SANUWAVE Health, despite recently lowering its sec
- RTTNews · Jul 1, 11:16 PM EDTTop Biotech Gainers: CANF Climbs, RGNT Gears Up For Europe Launch, RNAZ, ELTX On Watch(RTTNews) – Today's leading biotech gainers include Can-Fite, following an update from its pancreatic cancer study; SeaStar Medical, driven by improving quarter-over-quarter revenue for its flagship product; and Elicio, which has refined its Phase 3 development strategy for ELI-0
- RTTNews · Jun 30, 10:40 PM EDTTop Biotech Gainers: ABVX Soars On UC Trial Data, PMN Eyes Alzheimer's Catalyst, TRAX In Focus(RTTNews) – Today's top gainers in the biotech space include Cuprina, which recently received FDA clearance for its maggot-based wound treatment; ABIVAX, following encouraging results from an ulcerative colitis study; ProMIS, which has a key catalyst to watch this quarter; and su
- RTTNews · Jun 10, 11:03 PM EDTTop Biotech Gainers: PBLS Soars Over 50%, CLOV Rallies On Legal Win, RNAZ, TMCI On Watch(RTTNews) – Today's top biotech gainers include Parabilis, following a strong debut on its first day of trading; Shoulder Innovations, which recently issued a rosy outlook for the year; and Clover Health, which won a legal victory in its dispute with the U.S. Department of Health
- RTTNews · Jun 3, 9:10 AM EDTPre-Market Movers: PMI, CNTB, RNAZ Chart The Course(RTTNews) – Pre-market trading is offering an early glimpse into biotech stocks likely to attract investor attention this Wednesday.
- RTTNews · Dec 12, 9:23 AM ESTTransCode's TTX-MC138 To Enter Phase 2a Trial As Part Of Quantum Leap PRE-I-SPY Platform(RTTNews) – TransCode Therapeutics, Inc. (RNAZ) and Quantum Leap Healthcare Collaborative, on Friday, announced a collaboration to evaluate TTX-MC138 in a Phase 2a dose-expansion trial.
- RTTNews · Oct 8, 8:24 AM EDTTransCode Acquires Polynoma From CK Life Sciences(RTTNews) – TransCode Therapeutics (RNAZ) has entered into a definitive agreement to acquire Polynoma, a privately-held biotechnology immuno-oncology company. Polynoma is developing a late-stage candidate, seviprotimut-L, a polyvalent shed antigen vaccine for the adjuvant treatme
- Zacks · Apr 18, 12:00 PM EDTAll You Need to Know About TransCode Therapeutics (RNAZ) Rating Upgrade to BuyTransCode Therapeutics (RNAZ) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for TransCode Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.